In the rapidly evolving landscape of biopharmaceutical innovation, the spotlight is increasingly shifting from purely scientific promise to tangible, operational capabilities. As licensing agreements become a primary engine for pipeline growth, the robustness and scalability of manufacturing processes – collectively known as Chemistry, Manufacturing, and Controls (CMC) – are emerging as critical determinants of asset value and deal confidence. Companies that proactively address CMC readiness are not only mitigating risks but are also unlocking significant opportunities in a market hungry for reliable, high-potential therapeutics.
n
The Shifting Paradigm in Biopharma Deals
n
The traditional framework for evaluating biopharmaceutical assets has historically centered on the elegance of the science, the preclinical data, and the promise of clinical efficacy. However, the modern biopharma industry, characterized by its reliance on external innovation and strategic partnerships, demands a more holistic assessment. Pharmaceutical companies are increasingly looking beyond their internal discovery engines to fuel their pipelines, making licensing and acquisition a cornerstone of their growth strategies. This necessitates a rigorous examination of an asset’s potential for successful translation from laboratory bench to patient bedside – a journey heavily influenced by manufacturing feasibility.
n
Out-licensing, where an innovator grants rights to another entity, and in-licensing, where a company acquires external rights, both hinge on a comprehensive understanding of an asset’s entire lifecycle. While the initial appeal of an asset may lie in its novel mechanism of action or promising clinical signals, the subsequent stages of development, regulatory submission, and commercial supply are intrinsically tied to manufacturing capabilities. Without a clear and demonstrable path to scalable, consistent, and cost-effective production, even the most groundbreaking scientific discovery can falter.
n
This operational imperative is particularly pronounced in the context of cross-border collaborations, with the Asia-Pacific region, and notably China, emerging as a significant hub for innovative drug development. Recent analyses, such as GlobalData’s 2026 conference insights, highlight a dramatic surge in US biopharma companies in-licensing assets from China. This trend was further underscored at the 2026 JP Morgan Healthcare Conference, where landmark deals like AbbVie’s $5.6 billion agreement for RemeGen’s bispecific antibody RC148 and Novartis’s collaboration worth over $1.6 billion with SciNeuro Pharmaceuticals for Alzheimer’s disease candidates exemplify the growing reliance on international partnerships.
n
Beyond cost efficiencies, the allure of these regions lies in their rapidly advancing research capabilities, accelerated clinical trial timelines, and the availability of a deeper pipeline of differentiated therapies. For instance, GSK’s substantial $12.5 billion out-licensing agreement with Jiangsu Hengrui in 2025 illustrates this burgeoning trend. However, these globalized deal structures amplify the importance of thorough CMC due diligence. A potential licensee must ascertain not only the scientific merit but also the reproducibility of the clinical product at scale, the data’s adequacy for regulatory filings in target markets, and the feasibility of transferring manufacturing knowledge across diverse companies, facilities, and geographical locations.
n
The Critical Role of CMC Due Diligence and Strategic CDMO Partnerships
n
The financial models underpinning biopharmaceutical asset valuation are multifaceted, encompassing revenue forecasts, development expenditures, patent exclusivity, competitive positioning, and the probability of regulatory and commercial success. Weak or unaddressed manufacturing assumptions can cast a long shadow over every one of these critical inputs. Conversely, robust evidence demonstrating process robustness, predictable cost of goods, scalable capacity, successful technology transfer, and a clear regulatory pathway can significantly bolster the confidence in the foundational assumptions driving asset valuation.
n
CMC due diligence is therefore not merely a procedural step but a strategic imperative. It involves a meticulous examination of whether the manufacturing process is well-understood and demonstrably scalable. This includes scrutinizing the suitability of analytical methods, validating the adequacy of stability data to support proposed shelf lives, and ensuring that drug substance and drug product specifications are scientifically justified. Furthermore, a comprehensive review should encompass the characterization of impurities and degradation products, the integrity of quality systems, the historical batch data, and prior interactions with regulatory agencies.
n
These investigations are crucial for uncovering potential liabilities that may not be immediately apparent from clinical data. More importantly, the insights gleaned from CMC due diligence serve as a vital strategic input, directly informing the technical, regulatory, and financial viability of an asset. An immature manufacturing process, for example, could necessitate significant additional development before pivotal trials can commence, thereby delaying timelines and increasing costs. Incomplete stability studies can hobble supply chain planning, and inadequate analytical methods can complicate regulatory submissions, especially in the event of manufacturing changes requiring comparability assessments. Moreover, overly optimistic cost-of-goods assumptions can undermine the commercial viability of even a highly promising therapy.
n
A recent webinar hosted by Thermo Fisher Scientific underscored these challenges, advocating for an "audit-ready CMC package." Such a package should feature traceable, consistent data, compelling evidence of process robustness, proactive scale-up planning, and a transparent narrative that clearly delineates knowns, unknowns, and proposed strategies for addressing knowledge gaps. This methodical approach empowers potential partners to distinguish between manageable development tasks and risks that could derail a program or necessitate a significant downward valuation adjustment. It also fortifies confidence in assumptions related to scalability, cost, capacity, technology transfer readiness, and the overall path to commercialization.
n
Anil Kane, Global Head of Technical and Scientific Affairs, Pharma Services at Thermo Fisher Scientific, articulated this point compellingly, stating, "The CMC package and due diligence act as a strategic gate to evaluate a variety of factors and the value of the asset." This perspective highlights how CMC preparedness is no longer an afterthought but a direct contributor to asset valuation.
n
The strategic engagement of a Contract Development and Manufacturing Organization (CDMO) with extensive experience across development, technology transfer, regulatory filings, and commercial supply can inject substantial value throughout the entire transaction lifecycle. Before a deal is struck, a CDMO can assist in constructing a compelling, licensing-ready CMC package, identifying potential deficiencies, and enhancing process and scale-up readiness. During the due diligence phase, they can provide crucial support for technical assessments, audits, gap analyses, manufacturing feasibility studies, cost and capacity estimations, and regulatory considerations. Post-signing, the CDMO acts as an execution partner, translating due diligence findings into tangible remediation, seamless technology transfer, efficient scale-up, robust regulatory support, and ultimately, reliable commercial supply.
n
Thermo Fisher Scientific shared an illustrative case from their webinar: supporting the drug product development, technology transfer, clinical manufacturing, and scale-up for a low-dose oncology tablet developed by an Asian biotech company. This work was subsequently subjected to rigorous audits and gap analyses by multiple prospective partners during their diligence processes. Ultimately, a global biopharmaceutical company acquired the asset in a deal exceeding $1 billion, a testament to how exemplary CMC execution can profoundly influence transaction confidence and directly enhance asset value.
n
Strategies for Maximizing Deal Success Through Enhanced CMC Readiness
n
To truly maximize the success of licensing transactions, companies must adopt a proactive approach to CMC readiness, viewing it not merely as a risk mitigation exercise but as a strategic enabler of value. This proactive stance begins with the meticulous development of an audit-ready CMC package. This comprehensive dossier should systematically integrate process knowledge, analytical methodologies, defined specifications, stability data, and historical batch records in a coherent, traceable, and easily accessible format.
n
Crucially, this package must clearly delineate between issues that have been definitively resolved and those that represent remaining development work. It should also articulate how critical quality attributes are vigilantly controlled, provide evidence substantiating process robustness, and detail the logistical and technical considerations for transferring the asset to a new facility or manufacturing partner. By presenting these aspects transparently and early in the process, potential licensees gain a clearer understanding of the scope of remaining work, preventing the assumption that every identified gap equates to a fundamental flaw.
n
Furthermore, licensing teams must meticulously account for potential variations in equipment, the intricacies of material sourcing, the stringent requirements for demonstrating comparability, the availability of manufacturing capacity, and the time investment necessary for completing any outstanding technical work. A clear assignment of responsibilities should be established well before negotiations reach their final stages, specifying which activities are prerequisites for signing the deal and which can be seamlessly integrated into the ongoing partnership.
n
An experienced CDMO can significantly fortify this preparatory phase by rigorously testing assumptions related to cost, timelines, process performance, and supply chain reliability. This independent validation serves to expose potential weaknesses before they become contentious negotiating points, thereby providing both parties with a more credible and data-driven foundation for valuation and risk allocation. Post-transaction, the same trusted CDMO partner can bridge the gap between assessment and execution, transforming diligence findings into concrete remediation efforts, facilitating technology transfer, and driving successful scale-up initiatives.
n
Anil Kane’s advice for companies embarking on this journey is unequivocal: "Build a licensing-ready data package, including well-organized, audit-ready documentation." He further emphasizes the paramount importance of transparency, ensuring that development, manufacturing, and analytical information is not only traceable and accessible but also presented in a consistently logical and understandable manner.
n
While clinical performance will undoubtedly remain the principal determinant of an asset’s ultimate success, a well-articulated and robust pathway from development to commercial supply can profoundly reduce uncertainty, elevate confidence in execution, and facilitate the alignment of terms that accurately reflect an asset’s true, inherent potential. In essence, CMC readiness, bolstered by the expertise of strategic CDMO partners, serves as a powerful catalyst for enhancing asset value and effectively mitigating the multifaceted risks inherent in biopharmaceutical innovation and commercialization.
nnnnnnnnn
